An interventional study of Minimally Invasive Hematoma Evacuation and Best Medical Therapy in Stroke Hemorrhagic, sponsored by Zhongming Qiu. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Zhongming Qiu · Not applicable, Interventional, and Treatment
Among 25 studies in Hemorrhagic Stroke with a site in China — 14 open to participants now, 14 under way, none of them phase 3. Hemorrhagic Stroke · China.
Among the 25 studies in Hemorrhagic Stroke with a site in China, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 with no phase, reaches primary completion later than 4 of the 13 other live ones, and was the 14th registered.
233 studies on the registry are indexed under Hemorrhagic Stroke; 93 are open to participants now.
Browse Hemorrhagic Stroke studies →14 of the 25 studies in Hemorrhagic Stroke with a site in China are open now. Recruiting first, the newest first:
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Sites in China
Duan Chuanzhi · Sites in China
Xiangya Hospital of Central South University · Sites in China
Beijing Hospital · Sites in China
The University of Hong Kong · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 62 Hemorrhagic Stroke studies recruiting now, 36 (58%) set no upper age limit and 7 (11%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 6
First in 2007; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 100 is above the median of 58 across 156 interventional studies indexed under Hemorrhagic Stroke.
Median enrollment 410 across the 14 interventional studies, 1,000 across the 11 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 25 have an industry lead sponsor. The 10 most frequent:
Zhongming Qiu is the lead sponsor of 11 studies on the registry; 11 are open to participants now.
Zhongming Qiu has 1 study filed under Hemorrhagic Stroke — fewer than ten, so there is no comparison to draw.
4 of the studies in Hemorrhagic Stroke with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06374823Capital Medical UniversityMultiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke | 2026-12 |
| NCT07736885First Teaching Hospital of Tianjin University of Traditional Chinese MedicineEvaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment | 2027-03-30 |
| NCT05891509Zhongming QiuDTI-guided Minimally Invasive Hematoma Evacuation for Intracerebral Hemorrhage | 2027-05-31 |
| NCT05300997The University of Hong KongTranslational Immunodiagnostics in Stroke (TrImS) | 2027-08-31 |
Among the 25 studies in Hemorrhagic Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intracerebral hemorrhage (ICH) is a devastating disease with high early mortality, unfavorable neurological outcomes, and high cost of care. To date, the role of DTI-guided minimally invasive hematoma evacuation in ICH is still uncertain.
The investigators will conduct a multicenter randomized controlled trial, as well as a concurrent prospective observational study including all ICH patients who decline participation in the trial and will therefore receive minimally invasive hematoma evacuation or best medical therapy and consent to be followed up. All participants will be followed up at the same time using the same outcomes measures. The primary outcome will be collected by a blinded assessor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will receive the intervention of minimally invasive hematoma evacuation and best medical therapy
Procedure: Minimally Invasive Hematoma Evacuation · Other: Best Medical Therapy
Subjects randomized to this arm will receive best medical therapy alone
Other: Best Medical Therapy
Procedure of minimally invasive hematoma evacuation PLUS best medical therapy
Best medical therapy
Proportion of score of 0-3 on the modified Rankin scale
Scores on the modified Rankin scale range from 0 to 6, with higher scores indicating greater disability.
Time frame: 180 days after randomization
Score of on the modified Rankin scale
Scores on the modified Rankin scale range from 0 to 6, with higher scores indicating greater disability.
Time frame: 180 days after randomization
Incidence of symptomatic intracranial hemorrhage
Symptomatic intracranial hemorrhage will be defined according the Heidelberg bleeding classification criteria
Time frame: 30 days after randomization
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for May 2027, 45 months after the start.
Of 75 non-industry interventional studies with no phase under Hemorrhagic Stroke, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 45 months is above that.
Counting every sponsor, half of 89 studies reached it within 36 months; a quarter within 14 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhongming Qiu